Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $154.5455.

Several equities research analysts have recently issued reports on CELC shares. Leerink Partners set a $155.00 price objective on shares of Celcuity in a research report on Tuesday, June 2nd. Craig Hallum restated a "buy" rating and set a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celcuity in a research report on Tuesday, September 1st. Guggenheim increased their price target on Celcuity from $165.00 to $175.00 and gave the company a "buy" rating in a report on Monday, August 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $155.00 price objective on shares of Celcuity in a research report on Friday, August 14th.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its position in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock valued at $34,000 after acquiring an additional 319 shares in the last quarter. US Bancorp DE lifted its position in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after purchasing an additional 1,167 shares in the last quarter. Parallel Advisors LLC purchased a new position in shares of Celcuity in the first quarter valued at $38,000. Finally, Meeder Asset Management Inc. purchased a new position in shares of Celcuity in the fourth quarter valued at $42,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $95.70 on Monday. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The stock has a market capitalization of $4.68 billion, a P/E ratio of -22.26 and a beta of 0.19. The stock has a 50-day simple moving average of $94.58 and a 200-day simple moving average of $106.78.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Equities analysts forecast that Celcuity will post -4.75 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source